The Current Ratio as of December 2025 (TTM) for Stayble Therapeutics AB (publ) (STABL.ST) is 7.18

According to Stayble Therapeutics AB (publ)’s latest financial reports and current stock price. The company's current Current Ratio is 7.18. This represents a change of 50.44% compared to the average of 4.77 of the last 4 quarters.

Stayble Therapeutics AB (publ) (STABL.ST) Historical Current Ratio (quarterly & annually)

How has STABL.ST Current Ratio performed in the past?

The mean historical Current Ratio of Stayble Therapeutics AB (publ) over the last ten years is 8.89. The current 7.18 Current Ratio has changed 7.98% with respect to the historical average. Over the past ten years (40 quarters), STABL.ST's Current Ratio was at its highest in in the June 2021 quarter at 63.53. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Stayble Therapeutics AB (publ) (STABL.ST) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Stayble Therapeutics AB (publ) Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Stayble Therapeutics AB (publ) (STABL.ST) Average Current Ratio

How has STABL.ST Current Ratio performed in the past?

The current Current Ratio of Stayble Therapeutics AB (publ) (STABL.ST) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Stayble Therapeutics AB (publ) (STABL.ST) Current Ratio vs. Peers

How is STABL.ST’s Current Ratio compared to its peers?

Stayble Therapeutics AB (publ)’s Current Ratio is greater than Fluicell AB (publ) (1.20), greater than Aptahem AB (publ) (3.92), greater than LIDDS AB (publ) (4.04), less than Spermosens AB (9.27), greater than Chordate Medical Holding AB (publ) (1.97), greater than Quia Pharma AB (publ) (0.09), greater than 2cureX AB (publ) (2.93), greater than Guard Therapeutics International AB (publ) (4.87), greater than S2Medical AB (publ) (0.75), greater than Prostatype Genomics AB (publ) (1.95),

Build a custom stock screener for Stayble Therapeutics AB (publ) (STABL.ST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Stayble Therapeutics AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Stayble Therapeutics AB (publ) (STABL.ST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Stayble Therapeutics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.